Therapeutic DLL4 binding proteins
First Claim
Patent Images
1. A binding protein comprising an antigen-binding domain capable of binding DLL4, wherein the antigen-binding domain comprises a set of six complementarity determining region (CDR) sequences:
- CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein;
(a) CDR-H1 is selected from the group consisting of;
residues 31-35 of SEQ ID NO;
157 (CDR-H1 38H12);
residues 31-35 of SEQ ID NO;
161 (CDR-H1 37D10);
residues 31-35 of SEQ ID NO;
163 (CDR-H1 32C7);
residues 31-35 of SEQ ID NO;
165 (CDR-H1 14G1);
residues 31-35 of SEQ ID NO;
167 (CDR-H1 14A11);
residues 31-35 of SEQ ID NO;
169 (CDR-H1 15D6);
residues 31-35 of SEQ ID NO;
179 (CDR-H1 VH.1 38H12);
residues 31-35 of SEQ ID NO;
180 (CDR-H1 VH.1a 38H12);
residues 31-35 of SEQ ID NO;
181 (CDR-H1 VH.1b 38H12); and
residues 31-35 of SEQ ID NO;
182 (CDR-H1 VH.2a 38H12);
(b) CDR-H2 is selected from the group consisting of;
residues 50-66 of SEQ ID NO;
157 (CDR-H2 38H12);
residues 50-68 of SEQ ID NO;
161 (CDR-H2 37D10);
residues 50-66 of SEQ ID NO;
163 (CDR-H2 32C7);
residues 50-66 of SEQ ID NO;
165 (CDR-H2 14G1);
residues 50-66 of SEQ ID NO;
167 (CDR-H2 14A11);
residues 50-66 of SEQ ID NO;
169 (CDR-H2 15D6);
residues 50-66 of SEQ ID NO;
179 (CDR-H2 VH.1 38H12);
residues 50-66 of SEQ ID NO;
180 (CDR-H2 VH.1a 38H12);
residues 50-66 of SEQ ID NO;
181 (CDR-H2 VH.1 b 38H12); and
residues 50-66 of SEQ ID NO;
182 (CDR-H2 VH.2a 38H12);
(c) CDR-H3 is selected from the group consisting of;
residues 99-107 of SEQ ID NO;
157 (CDR-H3 38H12);
residues 101-111 of SEQ ID NO;
161 (CDR-H3 37D10);
residues 99-105 of SEQ ID NO;
163 (CDR-H3 32C7);
residues 99-105 of SEQ ID NO;
165 (CDR-H3 14G1);
residues 99-110 of SEQ ID NO;
167 (CDR-H3 14A11);
residues 99-110 of SEQ ID NO;
169 (CDR-H3 15D6);
residues 99-107 of SEQ ID NO;
179 (CDR-H3 VH.1 38H12);
residues 99-107 of SEQ ID NO;
180 (CDR-H3 VH.1a 38H12);
residues 99-107 of SEQ ID NO;
181 (CDR-H3 VH.1 b 38H12); and
residues 99-107 of SEQ ID NO;
182 (CDR-H3 VH.2a 38H12);
(d) CDR-L1 is selected from the group consisting of;
residues 24-34 of SEQ ID NO;
158 (CDR-L1 38H12);
residues 24-34 of SEQ ID NO;
162 (CDR-L1 37D10);
residues 24-34 of SEQ ID NO;
164 (CDR-L1 32C7);
residues 24-34 of SEQ ID NO;
166 (CDR-L1 14G1);
residues 23-37 of SEQ ID NO;
168 (CDR-L1 14A11);
residues 23-37 of SEQ ID NO;
170 (CDR-L1 15D6);
residues 24-34 of SEQ ID NO;
183 (CDR-L1 VL.1 38H12);
residues 24-34 of SEQ ID NO;
184 (CDR-L1 VL.1a 38H12);
residues 24-34 of SEQ ID NO;
185 (CDR-L1 VL.1b 38H12); and
residues 24-34 of SEQ ID NO;
186 (CDR-L1 VL.2a 38H12);
(e) CDR-L2 is selected from group consisting of;
residues 50-56 of SEQ ID NO;
158 (CDR-L2 38H12);
residues 50-56 of SEQ ID NO;
162 (CDR-L2 37D10);
residues 50-56 of SEQ ID NO;
164 (CDR-L2 32C7);
residues 50-56 of SEQ ID NO;
166 (CDR-L2 14G1);
residues 53-59 of SEQ ID NO;
168 (CDR-L2 14A11);
residues 53-59 of SEQ ID NO;
170 (CDR-L2 15D6);
residues 50-56 of SEQ ID NO;
183 (CDR-L2 VL.1 38H12);
residues 50-56 of SEQ ID NO;
184 (CDR-L2 VL.1a 38H12);
residues 50-56 of SEQ ID NO;
185 (CDR-L2 VL.1b 38H12); and
residues 50-56 of SEQ ID NO;
186 (CDR-L2 VL.2a 38H12);
and(f) CDR-L3 is selected from the group consisting of;
residues 89-97 of SEQ ID NO;
158 (CDR-L3 38H12);
residues 89-97 of SEQ ID NO;
162 (CDR-L3 37D10);
residues 89-98 of SEQ ID NO;
164 (CDR-L3 32C7);
residues 89-97 of SEQ ID NO;
166 (CDR-L3 14G1);
residues 92-100 of SEQ ID NO;
168 (CDR-L3 14A11);
residues 92-100 of SEQ ID NO;
170 (CDR-L3 15D6);
residues 89-97 of SEQ ID NO;
183 (CDR-L3 VL.1 38H12);
residues 89-97 of SEQ ID NO;
184 (CDR-L3 VL.1a 38H12);
residues 89-97 of SEQ ID NO;
185 (CDR-L3 VL.1b 38H12); and
residues 89-97 of SEQ ID NO;
186 (CDR-L3 VL.2a 38H12).
0 Assignments
0 Petitions
Accused Products
Abstract
DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
-
Citations
39 Claims
-
1. A binding protein comprising an antigen-binding domain capable of binding DLL4, wherein the antigen-binding domain comprises a set of six complementarity determining region (CDR) sequences:
- CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein;
(a) CDR-H1 is selected from the group consisting of; residues 31-35 of SEQ ID NO;
157 (CDR-H1 38H12);residues 31-35 of SEQ ID NO;
161 (CDR-H1 37D10);residues 31-35 of SEQ ID NO;
163 (CDR-H1 32C7);residues 31-35 of SEQ ID NO;
165 (CDR-H1 14G1);residues 31-35 of SEQ ID NO;
167 (CDR-H1 14A11);residues 31-35 of SEQ ID NO;
169 (CDR-H1 15D6);residues 31-35 of SEQ ID NO;
179 (CDR-H1 VH.1 38H12);residues 31-35 of SEQ ID NO;
180 (CDR-H1 VH.1a 38H12);residues 31-35 of SEQ ID NO;
181 (CDR-H1 VH.1b 38H12); andresidues 31-35 of SEQ ID NO;
182 (CDR-H1 VH.2a 38H12);(b) CDR-H2 is selected from the group consisting of; residues 50-66 of SEQ ID NO;
157 (CDR-H2 38H12);residues 50-68 of SEQ ID NO;
161 (CDR-H2 37D10);residues 50-66 of SEQ ID NO;
163 (CDR-H2 32C7);residues 50-66 of SEQ ID NO;
165 (CDR-H2 14G1);residues 50-66 of SEQ ID NO;
167 (CDR-H2 14A11);residues 50-66 of SEQ ID NO;
169 (CDR-H2 15D6);residues 50-66 of SEQ ID NO;
179 (CDR-H2 VH.1 38H12);residues 50-66 of SEQ ID NO;
180 (CDR-H2 VH.1a 38H12);residues 50-66 of SEQ ID NO;
181 (CDR-H2 VH.1 b 38H12); andresidues 50-66 of SEQ ID NO;
182 (CDR-H2 VH.2a 38H12);(c) CDR-H3 is selected from the group consisting of; residues 99-107 of SEQ ID NO;
157 (CDR-H3 38H12);residues 101-111 of SEQ ID NO;
161 (CDR-H3 37D10);residues 99-105 of SEQ ID NO;
163 (CDR-H3 32C7);residues 99-105 of SEQ ID NO;
165 (CDR-H3 14G1);residues 99-110 of SEQ ID NO;
167 (CDR-H3 14A11);residues 99-110 of SEQ ID NO;
169 (CDR-H3 15D6);residues 99-107 of SEQ ID NO;
179 (CDR-H3 VH.1 38H12);residues 99-107 of SEQ ID NO;
180 (CDR-H3 VH.1a 38H12);residues 99-107 of SEQ ID NO;
181 (CDR-H3 VH.1 b 38H12); andresidues 99-107 of SEQ ID NO;
182 (CDR-H3 VH.2a 38H12);(d) CDR-L1 is selected from the group consisting of; residues 24-34 of SEQ ID NO;
158 (CDR-L1 38H12);residues 24-34 of SEQ ID NO;
162 (CDR-L1 37D10);residues 24-34 of SEQ ID NO;
164 (CDR-L1 32C7);residues 24-34 of SEQ ID NO;
166 (CDR-L1 14G1);residues 23-37 of SEQ ID NO;
168 (CDR-L1 14A11);residues 23-37 of SEQ ID NO;
170 (CDR-L1 15D6);residues 24-34 of SEQ ID NO;
183 (CDR-L1 VL.1 38H12);residues 24-34 of SEQ ID NO;
184 (CDR-L1 VL.1a 38H12);residues 24-34 of SEQ ID NO;
185 (CDR-L1 VL.1b 38H12); andresidues 24-34 of SEQ ID NO;
186 (CDR-L1 VL.2a 38H12);(e) CDR-L2 is selected from group consisting of; residues 50-56 of SEQ ID NO;
158 (CDR-L2 38H12);residues 50-56 of SEQ ID NO;
162 (CDR-L2 37D10);residues 50-56 of SEQ ID NO;
164 (CDR-L2 32C7);residues 50-56 of SEQ ID NO;
166 (CDR-L2 14G1);residues 53-59 of SEQ ID NO;
168 (CDR-L2 14A11);residues 53-59 of SEQ ID NO;
170 (CDR-L2 15D6);residues 50-56 of SEQ ID NO;
183 (CDR-L2 VL.1 38H12);residues 50-56 of SEQ ID NO;
184 (CDR-L2 VL.1a 38H12);residues 50-56 of SEQ ID NO;
185 (CDR-L2 VL.1b 38H12); andresidues 50-56 of SEQ ID NO;
186 (CDR-L2 VL.2a 38H12);and (f) CDR-L3 is selected from the group consisting of; residues 89-97 of SEQ ID NO;
158 (CDR-L3 38H12);residues 89-97 of SEQ ID NO;
162 (CDR-L3 37D10);residues 89-98 of SEQ ID NO;
164 (CDR-L3 32C7);residues 89-97 of SEQ ID NO;
166 (CDR-L3 14G1);residues 92-100 of SEQ ID NO;
168 (CDR-L3 14A11);residues 92-100 of SEQ ID NO;
170 (CDR-L3 15D6);residues 89-97 of SEQ ID NO;
183 (CDR-L3 VL.1 38H12);residues 89-97 of SEQ ID NO;
184 (CDR-L3 VL.1a 38H12);residues 89-97 of SEQ ID NO;
185 (CDR-L3 VL.1b 38H12); andresidues 89-97 of SEQ ID NO;
186 (CDR-L3 VL.2a 38H12). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)
- CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein;
Specification